GH Research PLC (GHRS)

IE — Healthcare Sector
Peers: MOLN  MNOV  ANEB  CSBR  CYT  MLYS  ELYM  JANX  RZLT  PMVP  PHVS  PEPG  GLUE  DSGN  HOWL  IKNA  STOK  RCUS  CGEM  ANNX  GPCR  RLAY 

Automate Your Wheel Strategy on GHRS

With Tiblio's Option Bot, you can configure your own wheel strategy including GHRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GHRS
  • Rev/Share 0.0
  • Book/Share 5.3459
  • PB 2.3195
  • Debt/Equity 0.0021
  • CurrentRatio 29.7104
  • ROIC -0.1657

 

  • MktCap 769148440.0
  • FreeCF/Share -0.7118
  • PFCF -18.6221
  • PE -17.0886
  • Debt/Assets 0.0021
  • DivYield 0
  • ROE -0.192

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed GHRS Cantor Fitzgerald -- Overweight -- $25 June 4, 2025
Initiation GHRS Guggenheim -- Buy -- $32 March 13, 2025
Initiation GHRS RBC Capital Mkts -- Outperform -- $31 March 7, 2025
Initiation GHRS Cantor Fitzgerald -- Overweight -- $14 Feb. 13, 2025

News

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
GHRS
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA).

Read More
image for news GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
ATAI, CMPS, CYBN, GHRS, MNMD
Published: June 18, 2025 by: Proactive Investors
Sentiment: Positive

The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.

Read More
image for news FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
GHRS
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business.

Read More
image for news GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
What Makes GH Research (GHRS) a New Buy Stock
GHRS
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news What Makes GH Research (GHRS) a New Buy Stock
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
GHRS
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024 Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), …

Read More
image for news GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

About GH Research PLC (GHRS)

  • IPO Date 2021-06-25
  • Website https://www.ghres.com
  • Industry Biotechnology
  • CEO Velichka Valcheva
  • Employees 50

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.